OptimizeRx Corp is experiencing a drop in share price due to heightened market volatility and concerns regarding Most Favored Nation pricing. This uncertainty could pose risks to the company’s financial outlook and investor confidence in the near term.
OPRX reported Q4 sales of $32.32 million, up 14% year-over-year. Adjusted EPS was 30 cents, exceeding analyst expectations. Full-year revenue reached $92.1 million, a 29% growth from last year. CEO highlights strategic positioning for future growth in digital healthcare. 2025 revenue projected at $100 million, surpassing consensus estimates.